Bladder cancer test offers results in 30 minutes

Cytogen Corp. and Matritech, Inc., offer the NMP22 BladderChek point-of-caretest for bladder cancer, which is now approved for detecting the disease.The product had been previously approved for monitoring patients who hadalready been diagnosed with bladder cancer.

Related Videos

Related Content

Advertisement

December 11th 2024

Expanded Access Program to provide real-world data on cretostimogene grenadenorepvec

Hannah Clarke

Cretostimogene grenadenorepvec is an investigational oncolytic immunotherapy for patients with BCG-unresponsive high-risk NMIBC.

November 27th 2024

Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

December 10th 2024

Quiz: CUA guidelines on germline genetic testing in prostate cancer

Urology Times staff

Test your knowledge of his quiz the Canadian Urological Association's recommendations for germline genetic testing in prostate cancer management.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

December 9th 2024

FDA grants clearance to NanoKnife System for prostate tissue ablation

Hannah Clarke

The clearance is supported by data from the PRESERVE trial, which evaluated the safety and effectiveness of the NanoKnife System in patients with intermediate-risk prostate cancer.

December 9th 2024

What drives malpractice lawsuits involving testicular cancer?

Benjamin P. Saylor

"We found that the majority of malpractice claims were filed in response to delayed diagnosis or treatment and no cases were filed in response to surveillance practices or surgical techniques," said Adri M. Durant, MD.

Related Content

Advertisement

December 11th 2024

Expanded Access Program to provide real-world data on cretostimogene grenadenorepvec

Hannah Clarke

Cretostimogene grenadenorepvec is an investigational oncolytic immunotherapy for patients with BCG-unresponsive high-risk NMIBC.

November 27th 2024

Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

December 10th 2024

Quiz: CUA guidelines on germline genetic testing in prostate cancer

Urology Times staff

Test your knowledge of his quiz the Canadian Urological Association's recommendations for germline genetic testing in prostate cancer management.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

December 9th 2024

FDA grants clearance to NanoKnife System for prostate tissue ablation

Hannah Clarke

The clearance is supported by data from the PRESERVE trial, which evaluated the safety and effectiveness of the NanoKnife System in patients with intermediate-risk prostate cancer.

December 9th 2024

What drives malpractice lawsuits involving testicular cancer?

Benjamin P. Saylor

"We found that the majority of malpractice claims were filed in response to delayed diagnosis or treatment and no cases were filed in response to surveillance practices or surgical techniques," said Adri M. Durant, MD.